Peter MacCallum Cancer Centre

Running trials

• Not yet recruiting

  A Master Trial Assessing the Technical Feasibility of First-In-Human Real-Time Image Guided Radiation Therapy Methods

  NCT06708221· University of Sydney· Source

• Not yet recruiting

  Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma

  NCT07840001· Phase 2· Peter MacCallum Cancer Centre, Australia· Source

• Not yet recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

  NCT07728188· Phase 3· AbbVie· Source

• Recruiting

  Evaluation of XYA02 in Patients With Advanced Solid Tumors

  NCT07670312· Phase 1/2· XYone Therapeutics, Inc· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma

  NCT07565285· Phase 2· Primmune Therapeutics, Inc.· Source

• Recruiting

  A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT07558915· Phase 1· Genentech, Inc.· Source

• Recruiting

  Intratumoral N17350 in Advanced Solid Tumors

  NCT07339176· Phase 1/2· Onchilles Pharma Inc· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Recruiting

  Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

  NCT07527858· Phase 2· Gilead Sciences· Source

• Recruiting

  Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease

  NCT07541391· Phase 1· Peter MacCallum Cancer Centre, Australia· Source

• Recruiting

  A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06769698· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

  NCT07297979· Phase 1· Amgen· Source

• Not yet recruiting

  Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)

  NCT07527819· Peter MacCallum Cancer Centre, Australia· Source

• Recruiting

  A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT07455851· Phase 1/2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

  NCT07491497· Phase 1/2· TRIANA Biomedicines, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

  NCT07258407· Phase 1/2· T.O.A.D. Oncology SA· Source

• Recruiting

  A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

  NCT07195916· Phase 1· Incyte Corporation· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

  NCT07244341· Phase 1· Daiichi Sankyo· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

  NCT06816927· Phase 2· Duke University· Source

• Recruiting

  A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

  NCT07278336· Phase 1· AbbVie· Source

• Recruiting

  A Study to Describe the Effect of Photobiomodulation (Low Level Laser Therapy) in Reducing the Severity and Incidence of Oral Mucositis (Oral Ulceration) in Oral Cancer Patients Undergoing Radiation Treatment

  NCT07387978· Peter MacCallum Cancer Centre, Australia· Source

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· BioNTech SE· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  PRIORITY-CONNECT 2 Trial

  NCT06976710· Surgical Outcomes Research Centre (SOuRCe)· Source

• Active, not recruiting

  Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

  NCT07140900· Phase 1· Amgen· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma

  NCT07138222· Peter MacCallum Cancer Centre, Australia· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· Phase 3· BeOne Medicines· Source

• Not yet recruiting

  Home-Based Photo-Biomodulation for Management of Lymphoedema and Radiation Fibrosis in Patients After Head and Neck Cancer: A Single-Arm Feasibility Trial

  NCT07139782· Peter MacCallum Cancer Centre, Australia· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

  NCT07147348· Phase 1/2· BioNTech SE· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source

• Recruiting

  A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06948318· Phase 3· Takeda· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Recruiting

  AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

  NCT07094113· Phase 1· Amgen· Source

• Recruiting

  A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.

  NCT06383338· Phase 1· Murdoch Childrens Research Institute· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

• Recruiting

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  NCT06765109· Phase 3· Nuvalent Inc.· Source

• Recruiting

  A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

  NCT07075185· Phase 1· Kelonia Therapeutics, Inc.· Source

• Recruiting

  A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

  NCT06892522· Phase 1/2· AbbVie· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· BeOne Medicines· Source

• Recruiting

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  NCT06340568· Phase 3· BioNTech SE· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

Showing 50 of 231.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer25 recruiting
• Childhood cancers16 recruiting
• Colorectal cancer15 recruiting
• Prostate cancer14 recruiting
• Metastatic breast cancer11 recruiting
• Head and neck cancer10 recruiting
• Melanoma9 recruiting
• Pancreatic cancer9 recruiting
• Multiple myeloma8 recruiting
• Sarcoma8 recruiting
• Chronic lymphocytic leukaemia6 recruiting
• Ovarian cancer6 recruiting
• Triple-negative breast cancer6 recruiting
• Kidney cancer4 recruiting
• Neuroendocrine tumours4 recruiting
• Endometrial cancer3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Glioblastoma3 recruiting
• Liver and biliary tract cancer3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Acute myeloid leukaemia2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Immune thrombocytopenia (ITP)2 recruiting
• Mantle cell lymphoma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Thyroid cancer2 recruiting
• Amyloidosis1 recruiting
• Bladder cancer1 recruiting
• Follicular lymphoma1 recruiting
• Hodgkin lymphoma1 recruiting

Closed trials

• Withdrawn

  Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

  NCT07090369· Phase 1· Peter MacCallum Cancer Centre, Australia· Source

• Recruiting

  A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  NCT06876662· Phase 4· Eli Lilly and Company· Source

• Terminated

  A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

  NCT06585488· Phase 1· BeOne Medicines· Source

• Terminated

  A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

  NCT06194877· Phase 1· MapKure, LLC· Source

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Boehringer Ingelheim· Source

• Terminated

  Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

  NCT06068868· Phase 1· AbbVie· Source

• Completed

  A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT05848011· Phase 2· MacroGenics· Source

• Recruiting

  Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

  NCT05876312· Phase 1/2· ADARx Pharmaceuticals, Inc.· Source

• Completed

  A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

  NCT05470140· Phase 1· Allotera Therapeutics· Source

• Terminated

  ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

  NCT05743036· Phase 1· K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc· Source

• Completed

  Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

  NCT05546476· Phase 2· Pfizer· Source

• Terminated

  Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

  NCT05425862· Phase 1· Peter MacCallum Cancer Centre, Australia· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Gilead Sciences· Source

• Terminated

  A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

  NCT05269355· Phase 2/3· PTC Therapeutics· Source

• Completed

  A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma

  NCT05187624· Phase 1· Hoffmann-La Roche· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Terminated

  NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

  NCT05252390· Phase 1· Nuvation Bio Inc.· Source

• Recruiting

  A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

  NCT05091424· Phase 1· Hoffmann-La Roche· Source

• Completed

  A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

  NCT04984356· Phase 1· Allotera Therapeutics· Source

• Completed

  Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction

  NCT04925648· Phase 2· St Vincent's Hospital, Sydney· Source

• Completed

  Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

  NCT05008224· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

  NCT05017662· Ariceum Therapeutics GmbH· Source

• Completed

  Hepatocellular Carcinoma Imaging Using PSMA PET/CT

  NCT05095519· Phase 2· Peter MacCallum Cancer Centre, Australia· Source

• Completed

  A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

  NCT04702737· Phase 1· Amgen· Source

• Terminated

  A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

  NCT04740918· Phase 3· Hoffmann-La Roche· Source

• Completed

  Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

  NCT04799249· Phase 3· G1 Therapeutics, Inc.· Source

• Withdrawn

  A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

  NCT04264806· Phase 2· Janssen Research & Development, LLC· Source

• Terminated

  A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

  NCT04832854· Phase 2· Hoffmann-La Roche· Source

• Completed

  Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

  NCT04744831· Phase 2· Daiichi Sankyo· Source

• Completed

  A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

  NCT04438304· Phase 2· Clarity Pharmaceuticals Ltd· Source

• Completed

  A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

  NCT04657224· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

  NCT04334759· Phase 3· PrECOG, LLC.· Source

• Terminated

  Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

  NCT04093362· Phase 3· Taiho Oncology, Inc.· Source

• Completed

  A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

  NCT04670679· Phase 1· Erasca, Inc.· Source

• Completed

  A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

  NCT04557150· Phase 1· Hoffmann-La Roche· Source

• Completed

  Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

  NCT04472598· Phase 3· AbbVie· Source

• Terminated

  Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

  NCT04383210· Phase 2· Elevation Oncology· Source

• Completed

  A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer

  NCT04468607· Phase 1· Genentech, Inc.· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Terminated

  Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial

  NCT04316013· Phase 3· Peter MacCallum Cancer Centre, Australia· Source

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Amgen· Source

• Completed

  A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

  NCT04285567· Phase 3· Hoffmann-La Roche· Source

• Completed

  Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

  NCT04221945· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

  NCT04294810· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

  NCT04172675· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

  NCT04215978· Phase 1· BeiGene· Source

• Completed

  SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

  NCT04090710· Phase 2· Ontario Clinical Oncology Group (OCOG)· Source

• Terminated

  A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

  NCT04244656· Phase 1· CRISPR Therapeutics AG· Source

• Recruiting

  A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

  NCT05999994· Phase 2· Eli Lilly and Company· Source

• Completed

  Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

  NCT04068181· Phase 2· Amgen· Source

Showing 50 of 83.

Conditions

Diseases this institution publishes on or runs trials for.

• Prostate cancer155 works · 46 trials
• Lung cancer90 works · 54 trials
• Melanoma57 works · 23 trials
• Ovarian cancer53 works · 15 trials
• Multiple myeloma46 works · 25 trials
• Sarcoma36 works · 14 trials
• Kidney cancer30 works · 9 trials
• Triple-negative breast cancer30 works · 11 trials
• Acute myeloid leukaemia26 works · 12 trials
• Metastatic breast cancer24 works · 20 trials
• Chronic lymphocytic leukaemia20 works · 20 trials
• Endometrial cancer15 works · 7 trials
• Hodgkin lymphoma14 works · 7 trials
• Myelodysplastic syndromes13 works · 5 trials
• Follicular lymphoma13 works · 6 trials
• Head and neck cancer13 works · 20 trials
• Mantle cell lymphoma12 works · 7 trials
• Cytomegalovirus infection9 works · 0 trials
• Myeloproliferative neoplasms7 works · 7 trials